Un homme vêtu d'un costume bleu marine, d'une cravate bleu clair et d'une chemise blanche sourit devant un arrière-plan flou représentant un cabinet d'avocats d'affaires.

Andrew E. Rawlins

Partenaire

Andrew E. Rawlins is a partner and transactional lawyer with over 30 years of experience in intellectual property, focusing his practice on technology-intensive matters. He is a member of the Health Care & Life Sciences Sector and the Automotive Industry Team.

Andrew structures and negotiates technology agreements to create business relationships between companies that leverage technology and create synergistic opportunities. Using his experience and focus on technology transactions, he works with clients to identify critical issues and efficiently complete deals. Throughout his career, he has assisted clients with other strategic intellectual-property issues, such as due diligence in commercial transactions, patent procurement and portfolio management, and opinions on validity and infringement.

His practice is informed by his prior experience as a patent examiner at the United States Patent and Trademark Office and having conducted patent litigation, including trials and arguments before various trial courts and the U.S. Court of Appeals for the Federal Circuit.

Andrew has particular experience in a variety of technology fields, including pharmaceuticals, biotechnology, medical devices, automotive, and consumer electronics.

Prix et reconnaissance

  • Avocat remarquable, Thomson Reuters (2025)
  • Recommended in the categories of patent licensing and transactional (2014 and 2015) and patent portfolio management and licensing (2016) by The Legal 500
  • Peer Review Rated in Martindale-Hubbell’s peer review rating system
  • Selected as a finalist for Washington Business Journal’s 2008 Top Washington Lawyers awards program
  • Advisory board member for BNA’s Medical Devices Law & Industry Report
  • Former member of the intellectual property advisory board for Law360

Affiliations

  • Association américaine du droit de la propriété intellectuelle
  • Association du barreau américain
September 17, 2024 Deals and Wins

Foley Represents TCGX as Lead Investor in $105M Series B Financing for Pathalys Pharma

Foley & Lardner LLP represented TCG Crossover (TCGX) as the lead investor in the $105 million Series B financing for Pathalys Pharma Inc., a private biopharmaceutical company in the late stages of developing treatments for kidney disease.
3 septembre 2024 Contrats et victoires

Foley représente ARCHIMED dans l'acquisition d'Irrimax Corporation

Foley & Lardner LLP a récemment représenté ARCHIMED, spécialiste mondial du capital-investissement dans le domaine de la santé, dans le cadre de son acquisition d'Irrimax Corporation, y compris sa société holding, Innovation Technologies, pour un montant non divulgué.
11 avril 2024 Accords et victoires

Foley Represents ARCHIMED in Acquisition of Majority Stake in Innovative Skincare Company Cellese

Foley & Lardner LLP represented global private equity health care specialist ARCHIMED in its acquisition of a majority stake in Cellese, a developer of innovative topical dermo cosmetics sold under the AnteAGE brand name.
27 septembre 2023 Accords et victoires

Foley représente Bioluminescence Ventures en tant qu'investisseur principal dans le cadre de l'extension du financement de série B de ReCode Therapeutics

Foley & Lardner LLP a représenté Bioluminescence Ventures en tant qu'investisseur principal dans le cadre de l'extension du financement de série B de 50 millions de dollars pour ReCode Therapeutics.
5 octobre 2022 Contrats et victoires

Foley représente Hanwha Impact Partners en tant qu'investisseur principal dans le cadre d'un financement de série C de 121 millions de dollars pour Cellarity

Foley & Lardner LLP a récemment représenté Hanwha Impact Partners en tant qu'investisseur principal dans le cadre du tour de financement de série C de 121 millions de dollars pour Cellarity, un développeur de thérapies comportementales cellulaires.
September 14, 2022 Deals and Wins

Foley Represents TCG Crossover as Lead Investor in EUR 49.2M Crossover Financing for Abivax

Foley & Lardner LLP recently represented TCG Crossover (TCGX) as the lead investor in the successful, oversubscribed EUR 49.2 million crossover financing for Abivax.